Karyopharm Therapeutics Inc.
Join Class Action »
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
If you bought Karyopharm securities between March 2, 2017 and February 22, 2019, and would like to join the action, please click “Join This Class Action,” above.
SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. – KPTI
New York, N.Y., July 30, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
To join the Karyopharm class action, go to http://zhanginvestorlaw.com/cases/karyopharm-therapeutics-inc/ or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) data from the Phase 2 SOPRA trial (“SOPRA”) demonstrated that the Company’s lead drug candidate, selinexor, was associated with significant toxicity, was not well-tolerated among patients with AML, and resulted in a higher risk of death; (2) patients experienced serious drug-related side effects, with eighty percent of the AML patients treated with selinexor trial experiencing a serious adverse event; (3) as a result, nearly half of the acute myeloid leukemia (“AML”) patients were forced to withdraw from the SOPRA trial because of drug-related toxicity (4) in addition, the toxicity profile of selinexor for the treatment of patients with multiple myeloma in Part 2 of the Phase 2b STORM study was similar to that observed in AML patients treated with selinexor in the SOPRA study; and (5) as a result, Karyopharm’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/karyopharm-therapeutics-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at email@example.com.
Zhang Investor Law represents investors worldwide.